|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Beer TM, Armstrong AJ, Rathkopf DE, Loriot
Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J,
Chowdhury S, et al: Enzalutamide in metastatic prostate cancer
before chemotherapy. N Engl J Med. 371:424–433. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Bono JS, Logothetis CJ, Molina A,
Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F,
et al: Abiraterone and increased survival in metastatic prostate
cancer. N Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davies AH, Beltran H and Zoubeidi A:
Cellular plasticity and the neuroendocrine phenotype in prostate
cancer. Nat Rev Urol. 15:271–286. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamada Y and Beltran H: Clinical and
biological features of neuroendocrine prostate cancer. Curr Oncol
Rep. 23:152021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zaffuto E, Pompe R, Zanaty M, Bondarenko
HD, Leyh-Bannurah SR, Moschini M, Dell'Oglio P, Gandaglia G,
Fossati N, Stabile A, et al: Contemporary incidence and cancer
control outcomes of primary neuroend ocrine prostate cancer: A SEER
database analysis. Clin Genitourin Cancer. 15:e793–e800. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Varga J and Greten FR: Cell plasticity in
epithelial homeostasis and tumorigenesis. Nat Cell Biol.
19:1133–1141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Y and Wang Y, Ci X, Choi SYC, Crea F,
Lin D and Wang Y: Molecular events in neuroendocrine prostate
cancer development. Nat Rev Urol. 18:581–596. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garabedian EM, Humphrey PA and Gordon JI:
A transgenic mouse model of metastatic prostate cancer originating
from neuroendocrine cells. Proc Natl Acad Sci USA. 95:15382–15387.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Merkens L, Sailer V, Lessel D, Janzen E,
Greimeier S, Kirfel J, Perner S, Pantel K, Werner S and von Amsberg
G: Aggressive variants of prostate cancer: Underlying mechanisms of
neuroendocrine transdifferentiation. J Exp Clin Cancer Res.
41:462022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Varma M, Lee MW, Tamboli P, Zarbo RJ,
Jimenez RE, Salles PGO and Amin MB: Morphologic criteria for the
diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A
study of 250 consecutive cases in a routine surgical pathology
practice. Arch Pathol Lab Med. 126:554–561. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Epstein JI, Amin MB, Beltran H, Lotan TL,
Mosquera JM, Reuter VE, Robinson BD, Troncoso P and Rubin MA:
Proposed morphologic classification of prostate cancer with
neuroendocrine differentiation. Am J Surg Pathol. 38:756–767. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spetsieris N, Boukovala M, Patsakis G,
Alafis I and Efstathiou E: Neuroendocrine and aggressive-variant
prostate cancer. Cancers. 12:37922014. View Article : Google Scholar
|
|
15
|
Weinstein MH, Partin AW, Veltri RW and
Epstein JI: Neuroendocrine differentiation in prostate cancer:
Enhanced prediction of progression after radical prostatectomy. Hum
Pathol. 27:683–687. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Theodorescu D, Broder SR, Boyd JC, Mills
SE and Frierson HF Jr: Cathepsin D and chromogranin A as predictors
of long term disease specific survival after radical prostatectomy
for localized carcinoma of the prostate. Cancer. 80:2109–2119.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berruti A, Mosca A, Tucci M, Terrone C,
Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, et
al: Independent prognostic role of circulating chromogranin A in
prostate cancer patients with hormone-refractory disease. Endocr
Relat Cancer. 12:109–117. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bostwick DG, Qian J, Pacelli A, Zincke H,
Blute M, Bergstralh EJ, Slezak JM and Cheng L: Neuroendocrine
expression in node positive prostate cancer: Correlation with
systemic progression and patient survival. J Urol. 168:1204–1211.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Conteduca V, Oromendia C, Eng KW, Bareja
R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento
O, et al: Clinical features of neuroendocrine prostate cancer. Eur
J Cancer. 121:7–18. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang HT, Yao YH, Li BG, Tang Y, Chang JW
and Zhang J: Neuroendocrine Prostate Cancer (NEPC) progressing from
conventional pr ostatic adenocarcinoma: Factors associated with
time to development of NEPC and survival from NEPC diagnosis-a
systematic review and pooled analysis. J Clin Oncol. 32:3383–3390.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Montanari M, Rossetti S, Cavaliere C,
D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E,
Iovane G, Piscitelli R, et al: Epithelial-mesenchymal transition in
prostate cancer: An overview. Oncotarget. 8:35376–35389. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kalluri R and Neilson EG:
Epithelial-mesenchymal transition and its implications for
fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Williams ED, Gao D, Redfern A and Thompson
EW: Controversies around epithelial-mesenchymal plasticity in
cancer metastasis. Nat Rev Cancer. 19:716–732. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tiwari R, Manzar N and Ateeq B: Dynamics
of cellular plasticity in prostate cancer progression. Front Mol
Biosci. 7:1302020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bakir B, Chiarella AM, Pitarresi JR and
Rustgi AK: EMT, MET, plasticity, and tumor metastasis. Trends Cell
Biol. 30:764–776. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu YN, Chen WY, Yeh HL, Chen WH, Jiang
KC, Li HR, Dung PVT, Chen ZQ, Lee WJ, Hsiao M, et al: MCTP1
increases the malignancy of androgen-deprived prostate cancer cells
by inducing neuroendocrine differentiation and EMT. Sci Signal.
17:eadc91422024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Conteduca V, Aieta M, Amadori D and De
Giorgi U: Neuroendocrine differentiation in prostate cancer:
Current and emerging therapy strategies. Crit Rev Oncol Hematol.
92:11–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Capp JP: Cancer stem cells: From
historical roots to a new perspective. J Oncol. 2019:51892322019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Phi LTH, Sari IN, Yang YG, Lee SH, Jun N,
Kim KS, Lee YK and Kwon HY: Cancer stem cells (CSCs) in drug
resistance and their therapeutic implications in cancer treatment.
Stem Cells Int. 2018:54169232018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ayob AZ and Ramasamy TS: Cancer stem cells
as key drivers of tumour progression. J Biomed Sci. 25:202018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nguyen LV, Vanner R, Dirks P and Eaves CJ:
Cancer stem cells: An evolving concept. Nat Rev Cancer. 12:133–143.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pekovic V and Hutchison CJ: Adult stem
cell maintenance and tissue regeneration in the ageing context: The
role for A-type lamins as intrinsic modulators of ageing in adult
stem cells and their niches. J Anat. 213:5–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ojo D, Lin X, Wong N, Gu Y and Tang D:
Prostate cancer stem-like cells contribute to the development of
castration-resistant prostate cancer. Cancers (Basel). 7:2290–2308.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brown TJ and James V: The role of
extracellular vesicles in the development of a cancer stem cell
microenvironment niche and potential therapeutic targets: A
systematic review. Cancers (Basel). 13:24352021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Plaks V, Kong N and Werb Z: The cancer
stem cell niche: How essential is the niche in regulating stemness
of tumor cells? Cell Stem Cell. 16:225–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Castellón EA, Indo S and Contreras HR:
Cancer Stemness/epithelial-mesenchymal transition axis influences
metastasis and castration resistance in prostate cancer: Potential
therapeutic target. Int J Mol Sci. 23:149172022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Walcher L, Kistenmacher AK, Suo H, Kitte
R, Dluczek S, Strauß A, Blaudszun AR, Yevsa T, Fricke S and
Kossatz-Boehlert U: Cancer stem cells-origins and biomarkers:
Perspectives for targeted personalized therapies. Front Immunol.
11:12802020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xin L, Lawson DA and Witte ON: The Sca-1
cell surface marker enriches for a prostate-regenerating cell
subpopulation that can initiate prostate tumorigenesis. Proc Natl
Acad Sci USA. 102:6942–6947. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Germann M, Wetterwald A, Guzmán-Ramirez N,
van der Pluijm G, Culig Z, Cecchini MG, Williams ED and Thalmann
GN: Stem-like cells with luminal progenitor phenotype survive
castration in human prostate cancer. Stem Cells. 30:1076–1086.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ma F, Chen D, Chen F, Chi Y and Han Z,
Feng X, Li X and Han Z: Human umbilical cord mesenchymal stem cells
promote breast cancer metastasis by Interleukin-8- and
Interleukin-6-Dependent Induction of CD44(+)/CD24(−) cells. Cell
Transplant. 24:2585–2599. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ji Y, Liu B, Chen L, Li A, Shen K, Su R,
Zhang W, Zhu Y, Wang Q and Xue W: Repurposing ketotifen as a
therapeutic strategy for neuroendocrine prostate cancer by
targeting the IL-6/STAT3 pathway. Cell Oncol (Dordr). 46:1445–1456.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kopczyńska E: Role of microRNAs in the
resistance of prostate cancer to docetaxel and paclitaxel. Contemp
Oncol (Pozn). 19:423–427. 2015.PubMed/NCBI
|
|
45
|
Verma P, Shukla N, Kumari S, Ansari MS,
Gautam NK and Patel GK: Cancer stem cell in prostate cancer
progression, metastasis and therapy resistance. Biochim Biophys
Acta Rev Cancer. 1878:1888872023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Castillo V, Valenzuela R, Huidobro C,
Contreras HR and Castellon EA: Functional characteristics of cancer
stem cells and their role in drug resistance of prostate cancer.
Int J Oncol. 45:985–994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Biserova K, Jakovlevs A, Uljanovs R and
Strumfa I: Cancer stem cells: Significance in origin, pathogenesis
and treatment of glioblastoma. Cells. 10:6212021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Garcia-Mayea Y, Mir C, Masson F, Paciucci
R and ME LL: Insights into new mechanisms and models of cancer stem
cell multidrug resistance. Semin Cancer Biol. 60:166–180. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Satar NA, Fakiruddin KS, Lim MN, Mok PL,
Zakaria N, Fakharuzi NA, Abd Rahman AZ, Zakaria Z, Yahaya BH and
Baharuddin P: Novel triple-positive markers identified in human
non-small cell lung cancer cell line with chemotherapy-resistant
and putative cancer stem cell characteristics. Oncol Rep.
40:669–681. 2018.PubMed/NCBI
|
|
50
|
Duran GE, Wang YC, Francisco EB, Rose JC,
Martinez FJ, Coller J, Brassard D, Vrignaud P and Sikic BI:
Mechanisms of resistance to cabazitaxel. Mol Cancer Ther.
14:193–201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: Integrating immunity's roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q,
Dong X, Li J, Liu F, Jia X, et al: Twist1 expression induced by
sunitinib accelerates tumor cell vasculogenic mimicry by increasing
the population of CD133+ cells in triple-negative breast cancer.
Mol Cancer. 13:2072014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu B, Li L, Yang G, Geng C, Luo Y, Wu W,
Manyam GC, Korentzelos D, Park S, Tang Z, et al: PARP inhibition
suppresses GR-MYCN-CDK5-RB1-E2F1 signaling and neuroendocrine
differentiation in castration-resistant prostate cancer. Clin
Cancer Res. 25:6839–6851. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang Z, Zhao Y, An Z and Li W: Molecular
links between angiogenesis and neuroendocrine phenotypes in
prostate cancer progression. Front Oncol. 9:14912020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang Y, Zheng D, Zhou T, Song H,
Hulsurkar M, Su N, Liu Y, Wang Z, Shao L, Ittmann M, et al:
Androgen deprivation promotes neuroendocrine differentiation and
angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers.
Nat Commun. 9:40802018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ci X, Hao J, Dong X, Choi SY, Xue H, Wu R,
Qu S, Gout PW, Zhang F, Haegert AM, et al: Heterochromatin protein
1α mediates development and aggressiveness of neuroendocrine
prostate cancer. Cancer Res. 78:2691–2704. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chang PC, Wang TY, Chang YT, Chu CY, Lee
CL, Hsu HW, Zhou TA, Wu Z, Kim RH, Desai SJ, et al: Autophagy
pathway is required for IL-6 induced neuroendocrine differen
tiation and chemoresistance of prostate cancer LNCaP cells. PLoS
One. 9:e885562014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhu Y, Liu C, Cui Y, Nadiminty N, Lou W
and Gao AC: Interleukin-6 induces neuroendocrine differentiation
(NED) through sup pression of RE-1 silencing transcription factor
(REST). Prostate. 74:1086–1094. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fang D and Kitamura H: Cancer stem cells
and epithelial-mesenchymal transition in urothelial carcinoma:
Possible pathways and potential therapeutic approaches. Int J Urol.
25:7–17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hiraga T, Ito S and Nakamura H: EpCAM
expression in breast cancer cells is associated with enhanced bone
metastasis formation. Int J Cancer. 138:1698–1708. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rycaj K, Li H, Zhou J, Chen X and Tang DG:
Cellular determinants and microenvironmental regulation of prostate
cancer metastasis. Semin Cancer Biol. 44:83–97. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jeon HM and Lee J: MET: Roles in
epithelial-mesenchymal transition and cancer stemness. Ann Transl
Med. 5:52017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ruppender NS, Morrissey C, Lange PH and
Vessella RL: Dormancy in solid tumors: Implications for prostate
cancer. Cancer Metastasis Rev. 32:501–509. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li H and Tang DG: Prostate cancer stem
cells and their potential roles in metastasis. J Surg Oncol.
103:558–562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Celià-Terrassa T and Kang Y: Metastatic
niche functions and therapeutic opportunities. Nat Cell Biol.
20:868–877. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Shiozawa Y, Pedersen EA, Havens AM, Jung
Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al:
Human prostate cancer metastases target the hematopoietic stem cell
niche to establish footholds in mouse bone marrow. J Clin Invest.
121:1298–1312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kim JK, Jung Y, Wang J, Joseph J, Mishra
A, Hill EE, Krebsbach PH, Pienta KJ, Shiozawa Y and Taichman RS:
TBK1 regulates prostate cancer dormancy through mTOR inhibition.
Neoplasia. 15:1064–1074. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Correnti M and Raggi C: Stem-like
plasticity and heterogeneity of circulating tumor cells: Current
status and prospect challenges in liver cancer. Oncotarget.
8:7094–7115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Han H, Wang Y, Curto J, Gurrapu S, Laudato
S, Rumandla A, Chakraborty G, Wang X, Chen H, Jiang Y, et al:
Mesenchymal and stem-like prostate cancer linked to therapy-induced
lineage plasticity and metastasis. Cell Rep. 39:1105952022.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wang H and Unternaehrer JJ:
Epithelial-mesenchymal transition and cancer stem cells: At the
crossroads of differentiation and dedifferentiation. Dev Dyn.
248:10–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li P, Wang J, Chu M, Zhang K, Yang R and
Gao WQ: Zeb1 promotes androgen independence of prostate cancer via
induction of stem cell-like properties. Exp Biol Med (Maywood).
239:813–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Tsai YC, Chen WY, Abou-Kheir W, Zeng T,
Yin JJ, Bahmad H, Lee YC and Liu YN: Androgen deprivation
therapy-induced epithelial-mesenchymal transition of prostate
cancer through downregulating SPDEF and activating CCL2. Biochim
Biophys Acta Mol Basis Dis. 1864:1717–1727. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sun Y, Wang BE, Leong KG, Yue P, Li L,
Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al: Androgen
deprivation causes epithelial-mesenchymal transition in the
prostate: Implications for androgen-deprivation therapy. Cancer
Res. 72:527–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tang Y, Hamburger AW, Wang L, Khan MA and
Hussain A: Androgen deprivation and stem cell markers in prostate
cancers. Int J Clin Exp Pathol. 3:128–138. 2009.PubMed/NCBI
|
|
75
|
Qin J, Liu X, Laffin B, Chen X, Choy G,
Jeter CR, Calhoun-Davis T, Li H, Palapattu GS, Pang S, et al: The
PSA(−/lo) prostate cancer cell population harbors self-renewing
long-term tumor-propagating cells that resist castration. Cell Stem
Cell. 10:556–569. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Rybak AP, He L, Kapoor A, Cutz JC and Tang
D: Characterization of sphere-propagating cells with stem-like
properties from DU145 prostate cancer cells. Biochim Biophys Acta.
1813:683–694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Han M, Li F, Zhang Y, Dai P, He J, Li Y,
Zhu Y, Zheng J, Huang H, Bai F, et al: FOXA2 drives lineage
plasticity and KIT pathway activation in neuroend ocrine prostate
cancer. Cancer Cell. 40:1306–1323.e8. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Nouruzi S, Ganguli D, Tabrizian N, Kobelev
M, Sivak O, Namekawa T, Thaper D, Baca SC, Freedman ML, Aguda A, et
al: ASCL1 activates neuronal stem cell-like lineage programming
through re modeling of the chromatin landscape in prostate cancer.
Natu Commun. 13:22822022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wang Z, Wang T, Hong D, Dong B, Wang Y,
Huang H, Zhang W, Lian B, Ji B, Shi H, et al: Single-cell
transcriptional regulation and genetic evolution of neuroe ndocrine
prostate cancer. iScience. 25:1045762022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Singh N, Ramnarine VR, Song JH, Pandey R,
Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, et
al: The long noncoding RNA H19 regulates tumor plasticity in
neuroendocrin e prostate cancer. Nat Commun. 12:73492021.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Long Z, Deng L, Li C, He Q, He Y, Hu X,
Cai Y and Gan Y: Loss of EHF facilitates the development of
treatment-induced neuroendocrine prostate cancer. Cell Death Dis.
12:462021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao
Y, Xu W, Niu Y, Cheng L, Maity SN, et al: LncRNA-p21 alters the
antiandrogen enzalutamide-induced prostate cancer neuroendocrine
differentiation via modulating the EZH2/STAT3 signaling. Nat
Commun. 10:25712019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Kaarijärvi R, Kaljunen H, Nappi L, Fazli
L, Kung SHY, Hartikainen JM, Paakinaho V, Capra J, Rilla K, Malinen
M, et al: DPYSL5 is highly expressed in treatment-induced
neuroendocrine prostate cancer and promotes lineage plasticity via
EZH2/PRC2. Commun Biol. 7:1082024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Shui X, Ren X, Xu R, Xie Q, Hu Y, Qin J,
Meng H, Zhang C, Zhao J and Shi C: Monoamine oxidase A drives
neuroendocrine differentiation in prostate cancer. Biochem Biophys
Res Commun. 606:135–141. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Chen R, Li Y, Buttyan R and Dong X:
Implications of PI3K/AKT inhibition on REST protein stability and
neur oendocrine phenotype acquisition in prostate cancer cells.
Oncotarget. 8:84863–84876. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Bishop JL, Thaper D, Vahid S, Davies A,
Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, et al:
The master neural transcription factor BRN2 is an androgen
receptor-suppressed driver of neuroendocrine differentiation in
prostate cancer. Cancer Discov. 7:54–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Nie J, Zhang P, Liang C, Yu Y and Wang X:
ASCL1-mediated ferroptosis resistance enhances the progress of
castrat ion-resistant prostate cancer to neurosecretory prostate
cancer. Free Radic Biol Med. 205:318–331. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Akamatsu S, Wyatt AW, Lin D, Lysakowski S,
Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, et al: The
placental gene PEG10 promotes progression of neuroendocrine prosta
te cancer. Cell reports. 12:922–936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Deep G, Jain AK, Ramteke A, Ting H,
Vijendra KC, Gangar SC, Agarwal C and Agarwal R: SNAI1 is critical
for the aggressiveness of prostate cancer cells with low
E-cadherin. Mol Cancer. 13:372014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Bae KM, Su Z, Frye C, McClellan S, Allan
RW, Andrejewski JT, Kelley V, Jorgensen M, Steindler DA, Vieweg J,
et al: Expression of pluripotent stem cell reprogramming factors by
prostate tumor initiating cells. J Urol. 183:2045–2053. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bae KM, Parker NN, Dai Y, Vieweg J and
Siemann DW: E-cadherin plasticity in prostate cancer stem cell
invasion. Am J Cancer Res. 1:71–84. 2011.PubMed/NCBI
|
|
92
|
Orellana-Serradell O, Herrera D, Castellon
EA and Contreras HR: The transcription factor ZEB1 promotes an
aggressive phenotype in prostate cancer cell lines. Asian J Androl.
20:294–299. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Chaffer CL, Marjanovic ND, Lee T, Bell G,
Kleer CG, Reinhardt F, D'Alessio AC, Young RA and Weinberg RA:
Poised chromatin at the ZEB1 promoter enables breast cancer cell
plasticity and enhances tumorigenicity. Cell. 154:61–74. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kong D, Banerjee S, Ahmad A, Li Y, Wang Z,
Sethi S and Sarkar FH: Epithelial to mesenchymal transition is
mechanistically linked with stem cell signatures in prostate cancer
cells. PLoS One. 5:e124452010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Akunuru S, James Zhai Q and Zheng Y:
Non-small cell lung cancer stem/progenitor cells are enriched in
multiple distinct phenotypic subpopulations and exhibit plasticity.
Cell Death Dis. 3:e3522012. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Soundararajan R, Paranjape AN, Maity S,
Aparicio A and Mani SA: EMT, stemness and tumor plasticity in
aggressive variant neuroendocrine prostate cancers. Biochim Biophys
Acta Rev Cancer. 1870:229–238. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
McKeithen D, Graham T, Chung LW and
Odero-Marah V: Snail transcription factor regulates neuroendocrine
differentiation in LNCaP prostate cancer cells. Prostate.
70:982–992. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Dicken H, Hensley PJ and Kyprianou N:
Prostate tumor neuroendocrine differentiation via EMT: The road
less traveled. Asian J Urol. 6:82–90. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Boyer LA, Lee TI, Cole MF, Johnstone SE,
Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG,
et al: Core transcriptional regulatory circuitry in human embryonic
stem cells. Cell. 122:947–956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Sarkar A and Hochedlinger K: The sox
family of transcription factors: Versatile regulators of stem and
progenitor cell fate. Cell Stem Cell. 12:15–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhang S and Cui W: Sox2, a key factor in
the regulation of pluripotency and neural differ entiation. World J
Stem Cells. 6:305–311. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Metz EP, Wilder PJ, Dong J, Datta K and
Rizzino A: Elevating SOX2 in prostate tumor cells upregulates
expression of neuro endocrine genes, but does not reduce the
inhibitory effects of enzalut amide. J Cell Physiol. 235:3731–3740.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Kwon OJ, Zhang L, Jia D and Xin L: Sox2 is
necessary for androgen ablation-induced neuroendocrine differe
ntiation from Pten null Sca-1+ prostate luminal cells.
Oncogene. 40:203–214. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Tiwari R, Manzar N, Bhatia V, Yadav A,
Nengroo MA, Datta D, Carskadon S, Gupta N, Sigouros M, Khani F, et
al: Androgen deprivation upregulates SPINK1 expression and
potentiates cel lular plasticity in prostate cancer. Nature Commun.
11:3842020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Li H, Wang L, Li Z, Geng X, Li M, Tang Q,
Wu C and Lu Z: SOX2 has dual functions as a regulator in the
progression of neuroendo crine prostate cancer. Lab Invest.
100:570–582. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Kregel S, Kiriluk KJ, Rosen AM, Cai Y,
Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ and Vander Griend
DJ: Sox2 is an androgen receptor-repressed gene that promotes
castration-r esistant prostate cancer. PLoS One. 8:e537012013.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Kareta MS, Gorges LL, Hafeez S, Benayoun
BA, Marro S, Zmoos AF, Cecchini MJ, Spacek D, Batista LF, O'Brien
M, et al: Inhibition of pluripotency networks by the Rb tumor
suppressor restricts reprogramming and tumorigenesis. Cell Stem
Cell. 16:39–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Lovnicki J, Gan Y, Feng T, Li Y, Xie N, Ho
CH, Lee AR, Chen X, Nappi L, Han B, et al: LIN28B promotes the
development of neuroendocrine prostate cancer. J Clin Invest.
130:5338–5348. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Yasumizu Y, Rajabi H, Jin C, Hata T,
Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, et al: MUC1-C
regulates lineage plasticity driving progression to neuroendocrine
prostate cancer. Nat Commun. 11:3382020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Patel GK, Dutta S, Syed MM, Ramachandran
S, Sharma M, Rajamanickam V, Ganapathy V, DeGraff DJ, Pruitt K,
Tripathi M, et al: TBX2 Drives Neuroendocrine Prostate Cancer
through Exosome-Mediated Re pression of miR-200c-3p. Cancers
(Basel). 13:50202021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Sotomayor P, Godoy A, Smith GJ and Huss
WJ: Oct4A is expressed by a subpopulation of prostate
neuroendocrine cells. Prostate. 69:401–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Quintanal-Villalonga A, Kawasaki K, Redin
E, Uddin F, Rakhade S, Durani V, Sabet A, Shafer M, Karthaus WR,
Zaidi S, et al: CDC7 inhibition impairs neuroendocrine
transformation in lung and prostate tumors through MYC degradation.
Signal Transduct Target Ther. 9:1892024. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Dardenne E, Beltran H, Benelli M, Gayvert
K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, et
al: N-Myc Induces an EZH2-mediated transcriptional program driving
neuroendocrine prostate cancer. Cancer Cell. 30:563–577. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Berger A, Brady NJ, Bareja R, Robinson B,
Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, et al:
N-Myc-mediated epigenetic reprogramming drives lineage plasticity
in advanced prostate cancer. J Clin Invest. 129:3924–3940. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Beltran H, Rickman DS, Park K, Chae SS,
Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, et
al: Molecular characterization of neuroendocrine prostate cancer
and identification of new drug targets. Cancer Discov. 1:487–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Otto T, Horn S, Brockmann M, Eilers U,
Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R,
Christiansen H, et al: Stabilization of N-Myc is a critical
function of Aurora A in human neuroblastoma. Cancer Cell. 15:67–78.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Brockmann M, Poon E, Berry T, Carstensen
A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, et
al: Small molecule inhibitors of aurora-a induce proteasomal
degradation of N-myc in childhood neuroblastoma. Cancer Cell.
24:75–89. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Quintanal-Villalonga Á, Chan JM, Yu HA,
Pe'er D, Sawyers CL, Sen T and Rudin CM: Lineage plasticity in
cancer: A shared pathway of therapeutic resistance. Nat Rev Clin
Oncol. 17:360–371. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
McQuillen CN and Brady NJ: ASCL1 drives
the development of neuroendocrine prostate cancer. Cancer Res.
84:3499–3501. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Davies A, Zoubeidi A and Selth LA: The
epigenetic and transcriptional landscape of neuroendocrine prostate
cancer. Endocr Relat Cancer. 27:R35–R50. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Clermont PL, Lin D, Crea F, Wu R, Xue H,
Wang Y, Thu KL, Lam WL, Collins CC, Wang Y, et al:
Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin
Epigenetics. 7:402015. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Donaldson-Collier MC, Sungalee S, Zufferey
M, Tavernari D, Katanayeva N, Battistello E, Mina M, Douglass KM,
Rey T, Raynaud F, et al: EZH2 oncogenic mutations drive epigenetic,
transcriptional, and struct ural changes within chromatin domains.
Nat Genet. 51:517–528. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Sreekumar A and Saini S: Role of
transcription factors and chromatin modifiers in driving linea ge
reprogramming in treatment-induced neuroendocrine prostate cancer.
Front Cell Dev Biol. 11:10757072023. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Paranjape AN, Soundararajan R, Werden SJ,
Joseph R, Taube JH, Liu H, Rodriguez-Canales J, Sphyris N, Wistuba
I, Miura N, et al: Inhibition of FOXC2 restores epithelial
phenotype and drug sensitivity in prostate cancer cells with
stem-cell properties. Oncogene. 35:5963–5976. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Zhou Q, Yang M, Fu J, Sun X, Wang J, Zhang
H, Hu J and Han B: KIF1A promotes neuroendocrine differentiation in
prostate cancer by regulating the OGT-mediated O-GlcNAcylation.
Cell Death Dis. 15:7962024. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ward C, Volpe G, Cauchy P, Ptasinska A,
Almaghrabi R, Blakemore D, Nafria M, Kestner D, Frampton J, Murphy
G, et al: Fine-tuning mybl2 is required for proper
mesenchymal-to-epithelial transition during somatic reprogramming.
Cell Rep. 24:1496–1511.e8. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
German B, Alaiwi SA, Ho KL, Nanda JS,
Fonseca MA, Burkhart DL, Sheahan AV, Bergom HE, Morel KL, Beltran
H, et al: MYBL2 drives prostate cancer plasticity: Inhibiting its
transcriptional target CDK2 for RB1-deficient neuroendocrine
prostate cancer. Cancer Res Commun. 4:2295–2307. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hsieh CL, Do AD, Hsueh CY, Raboshakga MO,
Thanh TN, Tai TT, Kung HJ and Sung SY: L1CAM mediates
neuroendocrine phenotype acquisition in prostate cancer cells.
Prostate. 84:1434–1447. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Ku SY, Rosario S, Wang Y, Mu P, Seshadri
M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, et al: Rb1
and Trp53 cooperate to suppress prostate cancer lineage plasticity,
metastasis, and antiandrogen resistance. Science. 355:78–83. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Mu P, Zhang Z, Benelli M, Karthaus WR,
Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, et al: SOX2
promotes lineage plasticity and antiandrogen resistance in TP53-
and RB1-deficient prostate cancer. Science. 355:84–88. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Beltran H, Oromendia C, Danila DC,
Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong
AJ, Stein M, Pinski J, et al: A Phase II Trial of the aurora kinase
a inhibitor alisertib for patients with castration-resistant and
neuroendocrine prostate cancer: Efficacy and biomarkers. Clin
Cancer Res. 25:43–51. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Blackhall F, Jao K, Greillier L, Cho BC,
Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, et
al: Efficacy and safety of rovalpituzumab tesirine compared with
topotecan as second-line therapy in DLL3-High SCLC: Results from
the phase 3 TAHOE study. J Thorac Oncol. 16:1547–1558. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Beltran H, Prandi D, Mosquera JM, Benelli
M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV,
Varambally S, et al: Divergent clonal evolution of
castration-resistant neuroendocrine prostate cancer. Nat Med.
22:298–305. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Takahashi K and Yamanaka S: Induction of
pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lin T, Chao C, Saito S, Mazur SJ, Murphy
ME, Appella E and Xu Y: p53 induces differentiation of mouse
embryonic stem cells by suppressing Nanog expression. Nat Cell
Biol. 7:165–171. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Luongo F, Colonna F, Calapà F, Vitale S,
Fiori ME and De Maria R: PTEN Tumor-suppressor: The dam of stemness
in cancer. Cancers (Basel). 11:10762019. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zou M, Toivanen R, Mitrofanova A, Floch N,
Hayati S, Sun Y, Le Magnen C, Chester D, Mostaghel EA, Califano A,
et al: Transdifferentiation as a mechanism of treatment resistance
in a mouse model of Castration-resistant prostate cancer. Cancer
Discov. 7:736–749. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Tan HL, Sood A, Rahimi HA, Wang W, Gupta
N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, et al: Rb
loss is characteristic of prostatic small cell neuroendocrine
carcinoma. Clin Cancer Res. 20:890–903. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Bracken AP, Pasini D, Capra M, Prosperini
E, Colli E and Helin K: EZH2 is downstream of the pRB-E2F pathway,
essential for proliferation and amplified in cancer. EMBO J.
22:5323–5335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Song Z, Cao Q, Guo B, Zhao Y, Li X, Lou N,
Zhu C, Luo G, Peng S, Li G, et al: Overexpression of RACGAP1 by
E2F1 promotes neuroendocrine differentiat ion of prostate cancer by
stabilizing EZH2 expression. Aging Dis. 14:1757–1774. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Zhou Z, Flesken-Nikitin A, Corney DC, Wang
W, Goodrich DW, Roy-Burman P and Nikitin AY: Synergy of p53 and Rb
deficiency in a conditional mouse model for metastatic prostate
cancer. Cancer Res. 66:7889–7898. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Rajabi H and Kufe D: MUC1-C Oncoprotein
integrates a program of EMT, epigenetic reprogramming and immune
evasion in human carcinomas. Biochim Biophys Acta Rev Cancer.
1868:117–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Tong D: Unravelling the molecular
mechanisms of prostate cancer evolution from genotype to phenotype.
Crit Rev Oncol Hematol. 163:1033702021. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Rajabi H, Hiraki M and Kufe D: MUC1-C
activates polycomb repressive complexes and downregulates tumor
suppressor genes in human cancer cells. Oncogene. 37:2079–2088.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Rajabi H, Ahmad R, Jin C, Joshi MD, Guha
M, Alam M, Kharbanda S and Kufe D: MUC1-C oncoprotein confers
androgen-independent growth of human prostate cancer cells.
Prostate. 72:1659–1668. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Hagiwara M, Yasumizu Y, Yamashita N,
Rajabi H, Fushimi A, Long MD, Li W, Bhattacharya A, Ahmad R, Oya M,
et al: MUC1-C activates the BAF (mSWI/SNF) complex in prostate
cancer stem cells. Cancer Res. 81:1111–1122. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Chang YT, Lin TP, Campbell M, Pan CC, Lee
SH, Lee HC, Yang MH, Kung HJ and Chang PC: REST is a crucial
regulator for acquiring EMT-like and stemness phenotypes in
hormone-refractory prostate cancer. Sci Rep. 7:427952017.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Chang YT, Lin TP, Tang JT, Campbell M, Luo
YL, Lu SY, Yang CP, Cheng TY, Chang CH, Liu TT, et al: HOTAIR is a
REST-regulated lncRNA that promotes neuroendocrine differe ntiation
in castration resistant prostate cancer. Cancer Lett. 433:43–52.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Lin YC, Chang YT, Campbell M, Lin TP, Pan
CC, Lee HC, Shih JC and Chang PC: MAOA-a novel decision maker of
apoptosis and autophagy in hormone refr actory neuroendocrine
prostate cancer cells. Sci Rep. 7:463382017. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Lee CF, Chen YA, Hernandez E, Pong RC, Ma
S, Hofstad M, Kapur P, Zhau H, Chung LW, Lai CH, et al: The central
role of Sphingosine kinase 1 in the development of neuroen docrine
prostate cancer (NEPC): A new targeted therapy of NEPC. Clin Transl
Med. 12:e6952022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
O'Reilly D, Johnson P and Buchanan PJ:
Hypoxia induced cancer stem cell enrichment promotes resistance to
androgen deprivation therapy in prostate cancer. Steroids.
152:1084972019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Alumkal JJ, Sun D, Lu E, Beer TM, Thomas
GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, et al:
Transcriptional profiling identifies an androgen receptor
activity-low, stemness program associated with enzalutamide
resistance. Proc Natl Acad SciUSA. 117:12315–12323. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Bishop JL, Thaper D and Zoubeidi A: The
multifaceted roles of STAT3 signaling in the progression of
prostate cancer. Cancers. 6:829–859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Albino D, Civenni G, Rossi S, Mitra A,
Catapano CV and Carbone GM: The ETS factor ESE3/EHF represses IL-6
preventing STAT3 activation and expansion of the prostate cancer
stem-like compartment. Oncotarget. 7:76756–76768. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Song N, Cui K, Zeng L, Li M, Fan Y, Shi P,
Wang Z, Su W and Wang H: Advance in the role of
chemokines/chemokine receptors in carcinogenesis: Focus on
pancreatic cancer. Eur J Pharmacol. 967:1763572024. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Deng S, Wang C, Wang Y, Xu Y, Li X,
Johnson NA, Mukherji A, Lo UG, Xu L, Gonzalez J, et al: Ectopic
JAK-STAT activation enables the transition to a stem-like and
multilineage state conferring AR-targeted therapy resistance. Nat
Cancer. 3:1071–1087. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Ware KE, Thomas BC, Olawuni PD, Sheth MU,
Hawkey N, Yeshwanth M, Miller BC, Vietor KJ, Jolly MK, Kim SY, et
al: A synthetic lethal screen for Snail-induced enzalutamide
resistance identifies JAK/STAT signaling as a therapeutic
vulnerability in prostate cancer. Front Mol Biosci. 10:11045052023.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Chen L, Wang Y and Zhang B:
Hypermethylation in the promoter region inhibits AJAP1 expression
and activates the JAK/STAT pathway to promote prostate cancer cell
migration and stem cell sphere formation. Pathol Res Pract.
241:1542242023. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Spiotto MT and Chung TD: STAT3 mediates
IL-6-induced neuroendocrine differentiation in prostate cancer
cells. Prostate. 42:186–195. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Smith ND, Schulze-Hoepfner FT, Veliceasa
D, Filleur S, Shareef S, Huang L, Huang XM and Volpert OV: Pigment
Epithelium-derived factor and interleukin-6 control prostate
neuroendocrine differentiation via feed-forward mechanism. J Urol.
179:2427–2434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Dai J, Keller J, Zhang J, Lu Y, Yao Z and
Keller ET: Bone morphogenetic protein-6 promotes osteoblastic
prostate cancer bone metastases through a dual mechanism. Cancer
Res. 65:8274–8285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Dubrovska A, Kim S, Salamone RJ, Walker
JR, Maira SM, García-Echeverría C, Schultz PG and Reddy VA: The
role of PTEN/Akt/PI3K signaling in the maintenance and viability of
prostate cancer stem-like cell populations. Proc Natl Acad Sci USA.
106:268–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Zhang A, Lau NA, Wong A, Brown LG, Coleman
IM, De Sarkar N, Li D, DeLucia DC, Labrecque MP, Nguyen HM, et al:
Concurrent targeting of HDAC and PI3K to overcome phenotypic
heterogeneity of castration-resistant and neuroendocrine prostate
cancers. Cancer Res Commun. 3:2358–2374. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Wu J, Cang S, Liu C, Ochiai W and Chiao
JW: Development of human prostate cancer stem cells involves
epigenomic alteration and PI3K/AKT pathway activation. Exp Hematol
Oncol. 9:122020. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Morell C, Bort A, Vara D, Ramos-Torres A,
Rodríguez-Henche N and Díaz-Laviada I: The cannabinoid WIN 55,212-2
prevents neuroendocrine differentiation of LNCaP prostate cancer
cells. Prostate Cancer Prostatic Dis. 19:248–257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Yoo YA, Kang MH, Kim JS and Oh SC: Sonic
hedgehog signaling promotes motility and invasiveness of gastric
cancer cells through TGF-beta-mediated activation of the ALK5-Smad
3 pathway. Carcinogenesis. 29:480–490. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Petrova R and Joyner AL: Roles for
Hedgehog signaling in adult organ homeostasis and repair.
Development. 141:3445–3457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Merchant AA and Matsui W: Targeting
Hedgehog-a cancer stem cell pathway. Clin Cancer Res. 16:3130–3140.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Chang HH, Chen BY, Wu CY, Tsao ZJ, Chen
YY, Chang CP, Yang CR and Lin DP: Hedgehog overexpression leads to
the formation of prostate cancer stem cells with metastatic
property irrespective of androgen receptor expression in the mouse
model. J Biomed Sci. 18:62011. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Wang L, Li H, Li Z, Li M, Tang Q, Wu C and
Lu Z: Smoothened loss is a characteristic of neuroendocrine
prostate cancer. Prostate. 81:508–520. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Kishore C and Zi X: Wnt Signaling and
therapeutic resistance in castration-resistant prostate cancer.
Curr Pharmacol Rep. 9:261–274. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Sha J, Han Q, Chi C, Zhu Y, Pan J, Dong B,
Huang Y, Xia W and Xue W: PRKAR2B promotes prostate cancer
metastasis by activating Wnt/β-catenin and inducing
epithelial-mesenchymal transition. J Cell Biochem. 119:7319–7327.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Duchartre Y, Kim YM and Kahn M: The Wnt
signaling pathway in cancer. Crit Rev Oncol Hematol. 99:141–149.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Bisson I and Prowse DM: WNT signaling
regulates self-renewal and differentiation of prostate cancer cells
with stem cell characteristics. Cell Res. 19:683–697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Pan KF, Lee WJ, Chou CC, Yang YC, Chang
YC, Chien MH, Hsiao M and Hua KT: Direct interaction of β-catenin
with nuclear ESM1 supports stemness of metastatic prostate cancer.
EMBO J. 40:e1054502021. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Manzar N, Khan UK, Goel A, Carskadon S,
Gupta N, Palanisamy N and Ateeq B: An integrative proteomics
approach identifies tyrosine kinase KIT as a therapeutic target for
SPINK1-positive prostate cancer. iScience. 27:1087942024.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Bland T, Wang J, Yin L, Pu T, Li J, Gao J,
Lin TP, Gao AC and Wu BJ: WLS-Wnt signaling promotes neuroendocrine
prostate cancer. iScience. 24:1019702021. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Uysal-Onganer P, Kawano Y, Caro M, Walker
MM, Diez S, Darrington RS, Waxman J and Kypta RM: Wnt-11 promotes
neuroendocrine-like differentiation, survival and migration of
prostate cancer cells. Mol Cancer. 9:552010. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Liu RJ, Xu ZP, Huang X, Xu B and Chen M:
Yin Yang 1 promotes the neuroendocrine differentiation of prostate
cancer cells via the non-canonical WNT pathway (FYN/STAT3). Clin
Transl Med. 13:e14222023. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Wen YC, Liu YN, Yeh HL, Chen WH, Jiang KC,
Lin SR, Huang J, Hsiao M and Chen WY: TCF7L1 regulates cytokine
response and neuroendocrine differentiation of prostate cancer.
Oncogenesis. 10:812021. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Terry S, Maillé P, Baaddi H, Kheuang L,
Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y,
et al: Cross modulation between the androgen receptor axis and
protocadherin-PC in mediating neuroendocrine transdifferentiation
and therapeutic resistance of prostate cancer. Neoplasia.
15:761–772. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Shan J, Al-Muftah MA, Al-Kowari MK,
Abuaqel SWJ, Al-Rumaihi K, Al-Bozom I, Li P and Chouchane L:
Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits
neuroendocrine differentiation in prostate cancer. Cell Death
Discov. 5:1392019. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Unno K, Chalmers ZR, Pamarthy S, Vatapalli
R, Rodriguez Y, Lysy B, Mok H, Sagar V, Han H, Yoo YA, et al:
Activated ALK cooperates with N-Myc via Wnt/β-Catenin signaling to
induce neuroendocrine prostate cancer. Cancer Res. 81:2157–2170.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Kar R, Jha NK, Jha SK, Sharma A, Dholpuria
S, Asthana N, Chaurasiya K, Singh VK, Burgee S and Nand P: A
‘NOTCH’ Deeper into the Epithelial-To-Mesenchymal Transition (EMT)
program in breast cancer. Genes (Basel). 10:9612019. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Timmerman LA, Grego-Bessa J, Raya A,
Bertrán E, Pérez-Pomares JM, Díez J, Aranda S, Palomo S, McCormick
F, Izpisúa-Belmonte JC, et al: Notch promotes
epithelial-mesenchymal transition during cardiac development and
oncogenic transformation. Genes Dev. 18:99–115. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Uribe-Etxebarria V, Pineda JR,
García-Gallastegi P, Agliano A, Unda F and Ibarretxe G: Notch and
wnt signaling modulation to enhance DPSC stemness and therapeutic
potential. Int J Mol Sci. 24:73892023. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Puca L, Gavyert K, Sailer V, Conteduca V,
Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L,
et al: Delta-like protein 3 expression and therapeutic targeting in
neuroendo crine prostate cancer. Sci Transl Med. 11:eaav08912019.
View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Danza G, Di Serio C, Rosati F, Lonetto G,
Sturli N, Kacer D, Pennella A, Ventimiglia G, Barucci R, Piscazzi
A, et al: Notch signaling modulates hypoxia-induced neuroendocrine
differentiati on of human prostate cancer cells. Mol Cancer Res.
10:230–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Menssouri N, Poiraudeau L, Helissey C,
Bigot L, Sabio J, Ibrahim T, Pobel C, Nicotra C, Ngo-Camus M,
Lacroix L, et al: Genomic profiling of metastatic
castration-resistant prostate cancer s amples resistant to
androgen-receptor pathway inhibitors. Clin Cancer Res.
29:4504–4517. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Docherty NG, O'Sullivan OE, Healy DA,
Murphy M, O'Neill AJ, Fitzpatrick JM and Watson RW:
TGF-beta1-induced EMT can occur independently of its proapoptotic
effects and is aided by EGF receptor activation. Am J Physiol Renal
Physiol. 290:F1202–F1212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Yu B, Su J, Shi Q, Liu Q, Ma J, Ru G,
Zhang L, Zhang J, Hu X and Tang J: KMT5A-methylated SNIP1 promotes
triple-negative breast cancer metastasis by activating YAP
signaling. Nat Commun. 13:21922022. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Jiao C, Meng T, Zhou C, Wang X, Wang P, Lu
M, Tan X, Wei Q, Ge X and Jin J: TGF-β signaling regulates SPOP
expression and promotes prostate cancer cell stemness. Aging
(Albany NY). 12:7747–7760. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Natani S, Sruthi KK, Asha SM, Khilar P,
Lakshmi PSV and Ummanni R: Activation of TGF-β-SMAD2 signaling by
IL-6 drives neuroendocrine differentiation of prostate cancer
through p38MAPK. Cell Signal. 91:1102402022. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M,
Qin Y, Sun K, Teng Y and Liu M: Cancer-associated fibroblast
(CAF)-derived IL32 promotes breast cancer cell invasion and
metastasis via integrin β3-p38 MAPK signalling. Cancer Lett.
442:320–332. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Tang T, Wang LX, Yang ML and Zhang RM:
lncRNA TPTEP1 inhibits stemness and radioresistance of glioma
through miR-106a-5p-mediated P38 MAPK signaling. Mol Med Rep.
22:4857–4867. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Du Y, Long Q, Zhang L, Shi Y, Liu X, Li X,
Guan B, Tian Y, Wang X, Li L and He D: Curcumin inhibits
cancer-associated fibroblast-driven prostate cancer invasion
through MAOA/mTOR/HIF-1α signaling. Int J Oncol. 47:2064–2072.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Han H, Li H, Ma Y, Zhao Z, An Q, Zhao J
and Shi C: Monoamine oxidase A (MAOA): A promising target for
prostate cancer therapy. Cancer Lett. 563:2161882023. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Weng CC, Ding PY, Liu YH, Hawse JR,
Subramaniam M, Wu CC, Lin YC, Chen CY, Hung WC and Cheng KH: Mutant
Kras-induced upregulation of CD24 enhances prostate cancer stemness
and bone metastasis. Oncogene. 38:2005–2019. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
De Luca P, Moiola CP, Zalazar F, Gardner
K, Vazquez ES and De Siervi A: BRCA1 and p53 regulate critical
prostate cancer pathways. Prostate Cancer Prostatic Dis.
16:233–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Wang Y, Zhang YX, Kong CZ, Zhang Z and Zhu
YY: Loss of P53 facilitates invasion and metastasis of prostate
cancer cells. Mol Cell Biochem. 384:121–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Ren D, Wang M, Guo W, Zhao X, Tu X, Huang
S, Zou X and Peng X: Wild-type p53 suppresses the
epithelial-mesenchymal transition and stemness in PC-3 prostate
cancer cells by modulating miR-145. Int J Oncol. 42:1473–1481.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Kogan-Sakin I, Tabach Y, Buganim Y,
Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A,
Goldfinger N, et al: Mutant p53(R175H) upregulates Twist1
expression and promotes epithelial-mesenchymal transition in
immortalized prostate cells. Cell Death Differ. 18:271–281. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Kumaraswamy A, Duan Z, Flores D, Zhang C,
Sehrawat A, Hu YM, Swaim OA, Rodansky E, Storck WK, Kuleape JA, et
al: LSD1 promotes prostate cancer reprogramming by repressing TP53
signaling independently of its demethylase function. JCI Insight.
8:e1674402023. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Chaves LP, Melo CM, Saggioro FP, Reis RBD
and Squire JA: Epithelial-mesenchymal transition signaling and
prostate cancer stem cells: Emerging biomarkers and opportunities
for precision therapeutics. Genes (Basel). 12:19002021. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Sadrkhanloo M, Paskeh MDA, Hashemi M,
Raesi R, Bahonar A, Nakhaee Z, Entezari M, Beig Goharrizi MAS,
Salimimoghadam S, Ren J, et al: New emerging targets in
osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in
carcinogenesis. Pathol Res Pract. 251:1549022023. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Mei W, Lin X, Kapoor A, Gu Y, Zhao K and
Tang D: The contributions of prostate cancer stem cells in prostate
cancer initiation and metastasis. Cancers (Basel). 11:4342019.
View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Kaushik G, Seshacharyulu P, Rauth S,
Nallasamy P, Rachagani S, Nimmakayala RK, Vengoji R, Mallya K,
Chirravuri-Venkata R, Singh AB, et al: Selective inhibition of
stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer
metastasis. Oncogene. 40:848–862. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Liu Q, Pang J, Wang LA, Huang Z, Xu J,
Yang X, Xie Q, Huang Y, Tang T, Tong D, et al: Histone demethylase
PHF8 drives neuroendocrine prostate cancer progres sion by
epigenetically upregulating FOXA2. J Pathol. 253:106–118. 253
View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Qi J, Pellecchia M and Ronai ZeA: The
Siah2-HIF-FoxA2 axis in prostate cancer-new markers and therapeu
tic opportunities. Oncotarget. 1:379–385. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Qi J, Nakayama K, Cardiff RD, Borowsky AD,
Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell
D, et al: Siah2-dependent concerted activity of HIF and FoxA2
regulates formatio n of neuroendocrine phenotype and neuroendocrine
prostate tumors. Cancer Cell. 18:23–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Masone MC: FOXA2-KIT-driven lineage
plasticity in NEPC. Nat Rev Urol. 20:82023. View Article : Google Scholar
|
|
215
|
Singh N, Padi SKR, Bearss JJ, Pandey R,
Okumura K, Beltran H, Song JH, Kraft AS and Olive V: PIM protein
kinases regulate the level of the long noncoding RNA H19 t o
control stem cell gene transcription and modulate tumor growth. Mol
Oncol. 14:974–990. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Lee AR, Gan Y, Tang Y and Dong X: A novel
mechanism of SRRM4 in promoting neuroendocrine prostate cancer
development via a pluripotency gene network. EBioMedicine.
35:167–177. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Fan L, Gong Y, He Y, Gao WQ, Dong X, Dong
B, Zhu HH and Xue W: TRIM59 is suppressed by androgen receptor and
acts to promote lineage plasticity and treatment-induced
neuroendocrine differentiation in pro state cancer. Oncogene.
42:559–571. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Monga J, Adrianto I, Rogers C, Gadgeel S,
Chitale D, Alumkal JJ, Beltran H, Zoubeidi A and Ghosh J: Tribbles
2 pseudokinase confers enzalutamide resistance in prostate ca ncer
by promoting lineage plasticity. J Biol Chem. 298:1015562022.
View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Kim S, Thaper D, Bidnur S, Toren P,
Akamatsu S, Bishop JL, Colins C, Vahid S and Zoubeidi A: PEG10 is
associated with treatment-induced neuroendocrine prostate can cer.
J Mol Endocrinol. 63:39–49. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Yoshie H, Sedukhina AS, Minagawa K, Oda K,
Ohnuma S, Yanagisawa N, Maeda I, Takagi M, Kudo H, Nakazawa R, et
al: A bioinformatics-to-clinic sequential approach to analysis of
prostate cancer biomarkers using TCGA datasets and clinical
samples: A new met hod for precision oncology? Oncotarget.
8:99601–99611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Choi WW, Boland JL and Lin J: ONECUT2 as a
key mediator of androgen receptor-independent cell growth and
neuroendocrine differentiation in castration-resistant prostate c
ancer. Cancer Drug Resist. 5:165–170. 2022.PubMed/NCBI
|
|
222
|
Tenjin Y, Kudoh S, Kubota S, Yamada T,
Matsuo A, Sato Y, Ichimura T, Kohrogi H, Sashida G, Sakagami T and
Ito T: Ascl1-induced Wnt11 regulates neuroendocrine
differentiation, cell proliferation, and E-cadherin expression in
small-cell lung cancer and Wnt11 regulates small-cell lung cancer
biology. Lab Invest. 99:1622–1635. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
DeLucia DC, Cardillo TM, Ang L, Labrecque
MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, da Costa RMG,
Corey E, et al: Regulation of CEACAM5 and Therapeutic Efficacy of
an Anti-CEACAM5-SN38 Antibody-drug conjugate in neuroendocrine
prostate cancer. Clin Cancer Res. 27:759–774. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Meder L, König K, Ozretić L, Schultheis
AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U,
Florin A, et al: NOTCH, ASCL1, p53 and RB alterations define an
alternative pathway dri ving neuroendocrine and small cell lung
carcinomas. Int J Cancer. 138:927–938. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Tang Q, Chen J, Di Z, Yuan W, Zhou Z, Liu
Z, Han S, Liu Y, Ying G, Shu X, et al: TM4SF1 promotes EMT and
cancer stemness via the Wnt/β-catenin/SOX2 pathway in colorectal
cancer. J Exp Clin Cancer Res. 39:2322020. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Zhang Z, Wang X, Kim M, He D, Wang C, Fong
KW and Liu X: Downregulation of EZH2 inhibits
epithelial-mesenchymal transition in enzalutamide-resistant
prostate cancer. Prostate. 83:1458–1469. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Mirzaei S, Gholami MH, Hushmandi K,
Hashemi F, Zabolian A, Canadas I, Zarrabi A, Nabavi N, Aref AR,
Crea F, et al: The long and short non-coding RNAs modulating EZH2
signaling in cancer. J Hematol Oncol. 15:182022. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Zhang W, Bado IL, Hu J, Wan YW, Wu L, Wang
H, Gao Y, Jeong HH, Xu Z, Hao X, et al: The bone microenvironment
invigorates metastatic seeds for further dissemination. Cell.
184:2471–2486.e20. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Kufe D: Dependence on MUC1-C in
progression of neuroendocrine prostate cancer. Int J Mol Sci.
24:37192023. View Article : Google Scholar : PubMed/NCBI
|
